Ryman Healthcare (RYM) delivered FY20 (March-ended) NPAT of $242m, up 6.6% YoY, well below prior November guidance of $250-265m, however the miss appears mainly due to the impact of COVID-19 on its key sales month of March.
Sales are improving
While April trading was also impacted by Covid-19, resales are up around 10% YoY since May 1. While new sales have lagged, RYM is optimistic that new unit sales will recover in NZ as the country is at Level 1 (i.e. no domestic restrictions, border still closed), reflecting some pent-up demand and RYM's reputation as